
Carlos Rodriguez-Galindo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3525873/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	0.6	1,040
2	Inactivation of the p53 pathway in retinoblastoma. Nature, 2006, 444, 61-66.	13.7	550
3	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workâ€up, and treatment for patients till the age of 18 years. Pediatric Blood and Cancer, 2013, 60, 175-184.	0.8	496
4	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	7.7	415
5	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5564-73.	3.3	355
6	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	0.6	335
7	Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. Journal of Clinical Oncology, 2015, 33, 3065-3073.	0.8	312
8	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 1364-1370.	3.2	251
9	Childhood cancer burden: a review of global estimates. Lancet Oncology, The, 2019, 20, e42-e53.	5.1	237
10	A proposal for an international retinoblastoma staging system. Pediatric Blood and Cancer, 2006, 47, 801-805.	0.8	225
11	Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatric Blood and Cancer, 2019, 66, e27929.	0.8	220
12	Analysis of prognostic factors in ewing sarcoma family of tumors. Cancer, 2007, 110, 375-384.	2.0	211
13	Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Medical and Pediatric Oncology, 2003, 40, 276-287.	1.0	179
14	Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncology, The, 2020, 21, e185-e224.	5.1	177
15	Langerhans cell histiocytosis. Blood, 2020, 135, 1319-1331.	0.6	173
16	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. JAMA Oncology, 2016, 2, 608.	3.4	172
17	Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin. Journal of Clinical Oncology, 2003, 21, 2019-2025.	0.8	167
18	Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 2015, 6, 6302.	5.8	166

#	Article	IF	CITATIONS
19	Global challenges in pediatric oncology. Current Opinion in Pediatrics, 2013, 25, 3-15.	1.0	164
20	Prevalence and Functional Consequence of <i>TP53</i> Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 602-609.	0.8	164
21	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer, 2016, 122, 3632-3640.	2.0	145
22	Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatric Blood and Cancer, 2007, 49, 817-819.	0.8	144
23	Survival after recurrence of Ewing Tumors. Cancer, 2002, 94, 561-569.	2.0	143
24	Carboplatin-Associated Ototoxicity in Children With Retinoblastoma. Journal of Clinical Oncology, 2012, 30, 1034-1041.	0.8	134
25	Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatric Blood and Cancer, 2005, 45, 265-273.	0.8	127
26	Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma. Journal of Clinical Oncology, 2014, 32, 3762-3770.	0.8	117
27	Retinoblastoma: One World, One Vision. Pediatrics, 2008, 122, e763-e770.	1.0	115
28	The COVIDâ€19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOPâ€E, SIOPâ€E, SIOPâ€PODC, IPSO, PROS, CCI, and St Jude Global. Pediatric Blood and Cancer, 2020, 67, e28409.	0.8	113
29	Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States. Journal of Clinical Oncology, 2015, 33, 195-201.	0.8	111
30	Recent advances in the understanding of Langerhans cell histiocytosis. British Journal of Haematology, 2012, 156, 163-172.	1.2	110
31	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
32	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology, 2012, 351, 37-43.	1.6	103
33	Retinoblastoma. Pediatric Clinics of North America, 2015, 62, 201-223.	0.9	102
34	PET-CT in pediatric Langerhans cell histiocytosis. Pediatric Radiology, 2007, 37, 615-622.	1.1	101
35	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081.	0.8	101
36	Differential features of nasopharyngeal carcinoma in children and adults: A SEER study. Pediatric Blood and Cancer, 2010, 55, 279-284.	0.8	99

#	Article	IF	CITATIONS
37	Early advice on managing children with cancer during the COVIDâ€19 pandemic and a call for sharing experiences. Pediatric Blood and Cancer, 2020, 67, e28327.	0.8	93
38	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncology, The, 2021, 22, 1416-1426.	5.1	93
39	Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis. Hematology/Oncology Clinics of North America, 2015, 29, 853-873.	0.9	91
40	ls adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the <scp>M</scp> alignant <scp>G</scp> erm <scp>C</scp> ell <scp>T</scp> umor <scp>I</scp> nternational <scp>C</scp> ollaborative. Cancer, 2016, 122, 230-237.	2.0	91
41	Is primitive neuroectodermal tumor of the kidney a distinct entity?. , 1997, 79, 2243-2250.		89
42	Treatment of metastatic retinoblastoma. Ophthalmology, 2003, 110, 1237-1240.	2.5	87
43	Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer, 2005, 103, 850-857.	2.0	87
44	Ethnic, Racial, and Socioeconomic Disparities in Retinoblastoma. JAMA Pediatrics, 2015, 169, 1096.	3.3	86
45	Global efforts toward the cure of childhood acute lymphoblastic leukaemia. The Lancet Child and Adolescent Health, 2018, 2, 440-454.	2.7	83
46	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. The Lancet Child and Adolescent Health, 2021, 5, 332-340.	2.7	83
47	Prognostic factors and longâ€ŧerm outcomes of childhood nasopharyngeal carcinoma. Cancer, 2011, 117, 197-206.	2.0	79
48	Primary Ewing tumor of the vertebrae: Clinical characteristics, prognostic factors, and outcome. Medical and Pediatric Oncology, 2001, 37, 30-35.	1.0	78
49	Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatric Blood and Cancer, 2013, 60, 1621-1625.	0.8	77
50	Asociación de Hemato-OncologÃa Pediátrica de Centro América (AHOPCA): A model for sustainable development in pediatric oncology. Pediatric Blood and Cancer, 2014, 61, 345-354.	0.8	76
51	Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood, 2019, 133, 1691-1694.	0.6	76
52	Treatment of retinoblastoma: Current status and future perspectives. Current Treatment Options in Neurology, 2007, 9, 294-307.	0.7	75
53	Outcome after local recurrence of osteosarcoma. Cancer, 2004, 100, 1928-1935.	2.0	73
54	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	2.0	73

#	Article	IF	CITATIONS
55	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	0.8	70
56	Improved outcomes after successful implementation of a pediatric early warning system (PEWS) in a resourceâ€limited pediatric oncology hospital. Cancer, 2017, 123, 2965-2974.	2.0	67
57	Hemangiopericytoma in children and infants. , 2000, 88, 198-204.		66
58	Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatric Blood and Cancer, 2004, 43, 229-236.	0.8	64
59	Validation of a Pediatric Early Warning Score in Hospitalized Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients. Pediatric Critical Care Medicine, 2016, 17, e146-e153.	0.2	64
60	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of Clinical Oncology, 2015, 33, 3018-3028.	0.8	63
61	Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors. Cancer, 2005, 104, 367-373.	2.0	62
62	Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology, The, 2019, 20, 719-727.	5.1	62
63	Extranodal Rosai-Dorfman Disease in Children. Journal of Pediatric Hematology/Oncology, 2004, 26, 19-24.	0.3	61
64	Team management, twinning, and telemedicine in retinoblastoma: A 3â€ŧier approach implemented in the first eye salvage program in Jordan. Pediatric Blood and Cancer, 2008, 51, 241-244.	0.8	60
65	Paediatric extracranial germ-cell tumours. Lancet Oncology, The, 2016, 17, e149-e162.	5.1	60
66	Treating Childhood Cancer in Low- and Middle-Income Countries. , 2015, , 121-146.		60
67	Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatric Blood and Cancer, 2018, 65, e26784.	0.8	59
68	Episcleral plaque brachytherapy for retinoblastoma. Pediatric Blood and Cancer, 2004, 43, 134-139.	0.8	56
69	Validation of a pediatric early warning system for hospitalized pediatric oncology patients in a resourceâ€limited setting. Cancer, 2017, 123, 4903-4913.	2.0	56
70	Development of retinoblastoma programs in Central America. Pediatric Blood and Cancer, 2009, 53, 42-46.	0.8	55
71	Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatric Blood and Cancer, 2015, 62, 982-987.	0.8	53
72	Upfront window vincristine/irinotecan treatment of highâ€risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer, 2017, 123, 2360-2367.	2.0	53

#	Article	IF	CITATIONS
73	Use of Preclinical Models to Improve Treatment of Retinoblastoma. PLoS Medicine, 2005, 2, e332.	3.9	52
74	Lack of Correlation between the Histologic and Magnetic Resonance Imaging Results of Optic Nerve Involvement in Eyes Primarily Enucleated for Retinoblastoma. Ophthalmology, 2009, 116, 1558-1563.	2.5	50
75	Clinical use of topoisomerase I inhibitors in anticancer treatment. Medical and Pediatric Oncology, 2000, 35, 385-402.	1.0	48
76	Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2017, 35, 3465-3473.	0.8	47
77	Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. American Journal of Hematology, 2002, 69, 179-184.	2.0	46
78	Pediatric sarcoma in Central America. Cancer, 2013, 119, 871-879.	2.0	45
79	Death Within 1 Month of Diagnosis in Childhood Cancer: An Analysis of Risk Factors and Scope of the Problem. Journal of Clinical Oncology, 2017, 35, 1320-1327.	0.8	43
80	Hematologic Abnormalities and Acute Myeloid Leukemia in Children and Adolescents Administered Intensified Chemotherapy for the Ewing Sarcoma Family of Tumors. The American Journal of Pediatric Hematology/oncology, 2000, 22, 321-329.	1.3	43
81	Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. Journal of Clinical Oncology, 2017, 35, 72-77.	0.8	42
82	Immunohistochemical Detection of Multidrug-Resistant Protein Expression in Retinoblastoma Treated by Primary Enucleation. , 2006, 47, 1269.		40
83	Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012, 118, 5663-5670.	2.0	40
84	PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1097-1106.	3.3	40
85	Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal of Clinical Oncology, 2019, 37, 3369-3376.	0.8	40
86	Reducing irinotecan-associated diarrhea in children. Pediatric Blood and Cancer, 2008, 50, 201-207.	0.8	39
87	Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer, 2001, 92, 1613-1620.	2.0	38
88	Neuronal Differentiation and Synaptogenesis in Retinoblastoma. Cancer Research, 2007, 67, 2701-2711.	0.4	38
89	Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium. European Journal of Cancer, 2018, 98, 30-37.	1.3	38
90	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal of Clinical Oncology, 2021, 39, 2463-2473.	0.8	38

#	Article	IF	CITATIONS
91	Barriers to effective treatment of pediatric solid tumors in middleâ€income countries: Can we make sense of the spectrum of nonbiologic factors that influence outcomes?. Cancer, 2014, 120, 112-125.	2.0	37
92	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
93	Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway. Oncotarget, 2016, 7, 56889-56903.	0.8	37
94	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. Journal of Pediatric Hematology/Oncology, 2002, 24, 250-255.	0.3	35
95	Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian Collaborative Study Group for Ewing Sarcoma Family Tumors-EWING1. Pediatric Blood and Cancer, 2015, 62, 1747-1753.	0.8	35
96	An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Populationâ€Based Evidence for a Cancer Predisposition Syndrome?. Pediatric Blood and Cancer, 2016, 63, 196-201.	0.8	35
97	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. American Journal of Bioethics, 2016, 16, 3-11.	0.5	35
98	Ocular Preservation After 36 Gy External Beam Radiation Therapy for Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2002, 24, 246-249.	0.3	34
99	Clofarabine salvage therapy for refractory highâ€risk langerhans cell histiocytosis. Pediatric Blood and Cancer, 2013, 60, E19-22.	0.8	34
100	Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation. Journal of Pediatric Hematology/Oncology, 2014, 36, e335-e340.	0.3	34
101	Socioeconomic Impact of Modern Multidisciplinary Management of Retinoblastoma. Pediatrics, 2006, 118, e331-e336.	1.0	33
102	Children's Oncology Group's 2013 blueprint for research: Rare tumors. Pediatric Blood and Cancer, 2013, 60, 1016-1021.	0.8	33
103	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. Journal of Clinical Oncology, 2017, 35, 3956-3963.	0.8	33
104	Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Journal of Clinical Oncology, 2019, 37, 2875-2882.	0.8	33
105	Clofarabine in refractory Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2008, 51, 703-706.	0.8	31
106	Costâ€benefit analysis of implementing a pediatric early warning system at a pediatric oncology hospital in a lowâ€middle income country. Cancer, 2019, 125, 4052-4058.	2.0	30
107	How Telemedicine and Centralized Care Changed the Natural History of Retinoblastoma in a Developing Country. Ophthalmology, 2021, 128, 130-137.	2.5	30
108	Effect on Ocular Survival of Adding Early Intensive Focal Treatments to a Two-Drug Chemotherapy Regimen in Patients With Retinoblastoma. American Journal of Ophthalmology, 2005, 140, 397.e1-397.e.	1.7	29

#	Article	IF	CITATIONS
109	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. Clinical Cancer Research, 2013, 19, 1740-1747.	3.2	29
110	Pediatric adrenocortical tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101448.	2.2	29
111	Developmental and Adaptive Functioning in Children With Retinoblastoma: A Longitudinal Investigation. Journal of Clinical Oncology, 2014, 32, 2788-2793.	0.8	28
112	Contribution of the <i>TP53</i> R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors. Cancer, 2017, 123, 3150-3158.	2.0	26
113	Racial and Ethnic Disparities in the Incidence of Pediatric Extracranial Embryonal Tumors. Journal of the National Cancer Institute, 2017, 109, .	3.0	26
114	Brain metastases in children with melanoma. Cancer, 1997, 79, 2440-2445.	2.0	25
115	Colorimetric and Longitudinal Analysis of Leukocoria in Recreational Photographs of Children with Retinoblastoma. PLoS ONE, 2013, 8, e76677.	1.1	25
116	Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. International Journal of Pediatric Otorhinolaryngology, 2010, 74, 1156-1163.	0.4	24
117	Qualitative Study of Pediatric Early Warning Systems' Impact on Interdisciplinary Communication in Two Pediatric Oncology Hospitals With Varying Resources. JCO Global Oncology, 2020, 6, 1079-1086.	0.8	24
118	Clinical and organizational risk factors for mortality during deterioration events among pediatric oncology patients in Latin America: A multicenter prospective cohort. Cancer, 2021, 127, 1668-1678.	2.0	24
119	Local control in childhood extremity sarcomas: Salvaging limbs and sparing function. Medical and Pediatric Oncology, 2003, 41, 584-587.	1.0	22
120	Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2006, 57, 15-24.	1.1	22
121	Ovarian function in female survivors after multimodal Ewing sarcoma therapy. Pediatric Blood and Cancer, 2015, 62, 341-345.	0.8	22
122	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. Clinical Cancer Research, 2016, 22, 6247-6255.	3.2	22
123	Displaced children with cancer in Lebanon: A sustained response to an unprecedented crisis. Cancer, 2018, 124, 1464-1472.	2.0	22
124	Political priority and pathways to scale-up of childhood cancer care in five nations. PLoS ONE, 2019, 14, e0221292.	1.1	22
125	Things that matter: Adolescent and young adult patients' priorities during cancer care. Pediatric Blood and Cancer, 2019, 66, e27883.	0.8	22
126	Internal hemipelvectomy in the management of pelvic Ewing sarcoma – are outcomes better than with radiation therapy?. Journal of Pediatric Surgery, 2014, 49, 1500-1504.	0.8	21

#	Article	IF	CITATIONS
127	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. Gynecologic Oncology, 2018, 150, 253-260.	0.6	21
128	Treating Pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatric Blood and Cancer, 2008, 51, 760-764.	0.8	20
129	Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2017, 35, 1203-1210.	0.8	20
130	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood, 2021, 138, 1677-1690.	0.6	20
131	Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321) Journal of Clinical Oncology, 2017, 35, 10506-10506.	0.8	20
132	Socioeconomic status and global variations in the incidence of neuroblastoma: call for support of population-based cancer registries in low-middle-income countries. Pediatric Blood and Cancer, 2017, 64, 321-323.	0.8	19
133	A phase IIa study of afuresertib, an oral panâ€AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2017, 64, e26325.	0.8	19
134	Transfer of complex frontline anticancer therapy to a developing country: The St. Jude osteosarcoma experience in Chile. Pediatric Blood and Cancer, 2008, 50, 1143-1146.	0.8	18
135	Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatric Blood and Cancer, 2010, 55, 47-54.	0.8	18
136	Synchronous and metachronous thyroid cancer in relation to Langerhans cell histiocytosis; involvement of <i>V600E BRAFâ€</i> mutation?. Pediatric Blood and Cancer, 2015, 62, 173-174.	0.8	18
137	Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26394.	0.8	18
138	Pediatric cancer communication in low―and middleâ€income countries: A scoping review. Cancer, 2020, 126, 5030-5039.	2.0	18
139	Clinical features and treatment of Langerhans cell histiocytosis. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2892-2902.	0.7	18
140	Incidence of New Tumor Formation in Patients with Hereditary Retinoblastoma Treated with Primary Systemic Chemotherapy: Is There a Preventive Effect?. Ophthalmology, 2007, 114, 2077-2082.e1.	2.5	17
141	Langerhans cell histiocytosis. Clinical and Translational Oncology, 2008, 10, 688-696.	1.2	17
142	Validation of a multiâ€modal treatment protocol for Ewing sarcoma—A report from the polish pediatric oncology group. Pediatric Blood and Cancer, 2014, 61, 2170-2174.	0.8	17
143	Management and follow-up of Ewing sarcoma patients with isolated lung metastases. Journal of Pediatric Surgery, 2016, 51, 1067-1071.	0.8	17
144	Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey. Journal of Global Oncology, 2018, 4, 1-11.	0.5	17

#	Article	IF	CITATIONS
145	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. Cancers, 2020, 12, 506.	1.7	17
146	Impact of the COVIDâ€19 pandemic on pediatric oncology providers globally: A mixedâ€methods study. Cancer, 2022, 128, 1493-1502.	2.0	17
147	Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments. Pediatric Blood and Cancer, 2009, 52, 351-356.	0.8	16
148	Functional Neuroimaging to Characterize Visual System Development in Children with Retinoblastoma. , 2011, 52, 2619.		16
149	5th International ACC Symposium: Hereditary Predisposition to Childhood ACC and the Associated Molecular Phenotype. Hormones and Cancer, 2016, 7, 36-39.	4.9	16
150	Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood and Cancer, 2018, 65, e26913.	0.8	16
151	Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Medical and Pediatric Oncology, 2001, 36, 605-611.	1.0	15
152	Correlation of Insurance, Race, and Ethnicity with Pathologic Risk in a Controlled Retinoblastoma Cohort. Ophthalmology, 2016, 123, 1817-1823.	2.5	15
153	Malignant glomus tumors of the head and neck in children and adults: Evaluation and management. Laryngoscope, 2017, 127, 2873-2882.	1.1	15
154	Addressing regional disparities in pediatric oncology: Results of a collaborative initiative across the Mexican–North American border. Pediatric Blood and Cancer, 2017, 64, e26387.	0.8	15
155	A longitudinal investigation of parenting stress in caregivers of children with retinoblastoma. Pediatric Blood and Cancer, 2017, 64, e26279.	0.8	14
156	Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion–negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2018, 124, 1973-1981.	2.0	14
157	Pediatric Early Warning Systems aid in triage to intermediate versus intensive care for pediatric oncology patients in resourceâ€imited hospitals. Pediatric Blood and Cancer, 2018, 65, e27076.	0.8	14
158	Clinician Emotions Surrounding Pediatric Oncology Patient Deterioration. Frontiers in Oncology, 2021, 11, 626457.	1.3	14
159	Impact of PEWS on Perceived Quality of Care During Deterioration in Children With Cancer Hospitalized in Different Resource-Settings. Frontiers in Oncology, 2021, 11, 660051.	1.3	14
160	Doxorubicin in combination with cisplatin, 5â€flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study. Cancer, 2022, 128, 1057-1065.	2.0	14
161	Adolescents and Young Adults With a "Rare―Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors. Oncologist, 2014, 19, 689-692.	1.9	13
162	Solid Cancers in the Premature and the Newborn: Report of Three National Referral Centers. Pediatrics and Neonatology, 2016, 57, 295-301.	0.3	13

#	Article	IF	CITATIONS
163	Pharmacological management of Ewing sarcoma family of tumours. Expert Opinion on Pharmacotherapy, 2004, 5, 1257-1270.	0.9	12
164	Expression of the Multi-Drug Resistance Proteins and the Pregnane X Receptor in Treated and Untreated Retinoblastoma. Current Eye Research, 2009, 34, 386-394.	0.7	12
165	Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric Blood and Cancer, 2017, 64, e26375.	0.8	12
166	Influence of early phase clinical trial enrollment on patterns of endâ€ofâ€life care for children with advanced cancer. Pediatric Blood and Cancer, 2018, 65, e26748.	0.8	12
167	Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children's Oncology Group ARAR0332 protocol Journal of Clinical Oncology, 2016, 34, 10515-10515.	0.8	12
168	Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. Journal of Clinical Oncology, 2022, 40, 459-467.	0.8	12
169	Sister Mary Joseph's nodule as presenting sign of a desmoplastic small round cell tumor. Pediatric Blood and Cancer, 2008, 50, 388-390.	0.8	11
170	Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. Pediatric Blood and Cancer, 2018, 65, e27111.	0.8	11
171	Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2019, 37, 396-402.	0.8	11
172	Spatial trends in congenital malformations and stream water chemistry in Southern Brazil. Science of the Total Environment, 2019, 650, 1278-1291.	3.9	11
173	Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer, 2021, 68, e29018.	0.8	11
174	Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of Clinical Oncology, 2022, 40, 3839-3847.	0.8	11
175	αâ€Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer, 2019, 125, 3649-3656.	2.0	10
176	Bridging the Gap in Access to Care for Children With CNS Tumors Worldwide. JCO Global Oncology, 2020, 6, 583-584.	0.8	10
177	Resilient health care in global pediatric oncology during the COVIDâ€19 pandemic. Cancer, 2022, 128, 797-807.	2.0	10
178	Delayed Diagnosis and False Relapse Due to Paternal Testosterone Use in Adrenocortical Carcinoma. Pediatrics, 2014, 133, e1772-e1776.	1.0	9
179	The Common Germline <i>TP53-R337H</i> Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research, 2021, 81, 2442-2456.	0.4	9
180	Imaging aspects of neurologic emergencies in children treated for non-CNS malignancies. Pediatric Radiology, 2000, 30, 558-565.	1.1	8

#	Article	IF	CITATIONS
181	Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium. Cancer, 2021, 127, 193-202.	2.0	8
182	The Global COVIDâ€19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. Pediatric Blood and Cancer, 2021, 68, e28962.	0.8	8
183	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Journal of Pediatrics, 2021, 237, 65-70.e3.	0.9	8
184	Trisomy of the Long Arm of Chromosome 1 Resulting in a Dicentric Derivative (6)t(1;6) Chromosome in a Child with Myelodysplastic Syndrome Following Treatment for a Primitive Neuroectodermal Tumor. Leukemia and Lymphoma, 2000, 37, 213-218.	0.6	7
185	The basics of retinoblastoma: Back to school. Pediatric Blood and Cancer, 2011, 57, 1093-1094.	0.8	7
186	Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatric Blood and Cancer, 2019, 66, e27469.	0.8	7
187	Pediatric Solid Tumors. , 2020, , 1703-1747.e11.		7
188	The evolution of parents' beliefs about childhood cancer during diagnostic communication: a qualitative study in Guatemala. BMJ Global Health, 2021, 6, e004653.	2.0	7
189	Aggressive treatment and survival outcomes in <i>NUT</i> midline carcinoma (NMC) of the head and neck (HN) Journal of Clinical Oncology, 2014, 32, 6057-6057.	0.8	7
190	Treatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children's Oncology Group ARAR0331 study Journal of Clinical Oncology, 2016, 34, 10513-10513.	0.8	7
191	Ewing Sarcoma Family of Tumors. , 2006, , 181-217.		6
192	Participation in an occupational therapy referral program for children with retinoblastoma. Journal of Pediatric Rehabilitation Medicine, 2016, 9, 117-124.	0.3	6
193	Training pediatric hematologist/oncologists for capacity building in Ethiopia. Pediatric Blood and Cancer, 2020, 67, e28760.	0.8	6
194	Creation of a successful multidisciplinary course in pediatric neuroâ€oncology with a systematic approach to curriculum development. Cancer, 2021, 127, 1126-1133.	2.0	6
195	Ewing sarcoma: investigational mono- and combination therapies in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 653-663.	1.9	6
196	Impact of central surgical review in a study of malignant germ cell tumors. Journal of Pediatric Surgery, 2015, 50, 1502-1505.	0.8	5
197	A sustainable model for pediatric oncology nursing education and capacity building in Latin American hospitals: Evolution and impact of a nurse educator network. Pediatric Blood and Cancer, 2021, 68, e29095.	0.8	5
198	Communication Priorities and Experiences of Caregivers of Children With Cancer in Guatemala. JCO Global Oncology, 2021, 7, 1529-1536.	0.8	5

#	Article	IF	CITATIONS
199	Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. Implementation Science Communications, 2022, 3, .	0.8	5
200	Treatment of Langerhans cell histiocytosis: it is time to learn from the past. British Journal of Haematology, 2015, 171, 148-149.	1.2	4
201	Joining forces for children with cancer in Latin America. Lancet Oncology, The, 2016, 17, 701-703.	5.1	4
202	Improving Immunohistochemistry Capability for Pediatric Cancer Care in the Central American and Caribbean Region: A Report From the AHOPCA Pathology Working Group. Journal of Global Oncology, 2018, 4, 1-9.	0.5	4
203	Paediatric Oncology System Integration Tool (POSIT) for the joint analysis of the performance of childhood cancer programs and health systems. Journal of Cancer Policy, 2020, 23, 100208.	0.6	4
204	Interdisciplinary care of pediatric oncology patients in Central America and the Caribbean. Cancer, 2020, 127, 2579-2586.	2.0	4
205	Assessment of Retinoblastoma Capacity in the Middle East, North Africa, and West Asia Region. JCO Global Oncology, 2020, 6, 1531-1539.	0.8	4
206	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. Ecancermedicalscience, 2021, 15, 1187.	0.6	4
207	Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age. Journal of Clinical Oncology, 2021, 39, 2676-2684.	0.8	4
208	Pediatric Solid Tumors. , 2008, , 2075-2129.		4
209	Clinical and Functional Significance of TP53 Exon 4–Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
210	Evaluation of Early Treatment Response Utilizing the MAS-ALL18 Adapted Management Guideline in Four <i>"Mexico in Alliance with St. Jude"</i> (MAS) Member Hospitals. Blood, 2021, 138, 1210-1210.	0.6	4
211	Successful Implementation of a Pediatric Early Warning Score in a Resource-Limited Pediatric Oncology Hospital in Guatemala. Journal of Global Oncology, 2016, 2, 60s-60s.	0.5	3
212	Risk of second gonadal cancers in women and children with germ cell tumors. Cancer, 2016, 122, 2076-2082.	2.0	3
213	Delivery of radiation therapy in resourceâ€iimited settings: A pilot quality assessment study. Pediatric Blood and Cancer, 2017, 64, e26480.	0.8	3
214	The Toronto Guidelines: a practical means for childhood cancer staging. The Lancet Child and Adolescent Health, 2018, 2, 158-159.	2.7	3
215	Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas. Journal of Global Oncology, 2019, 5, 1-7.	0.5	3
216	Development, Implementation, and Outcomes of a Global Infectious Disease Training Course. Journal of Medical Education and Curricular Development, 2021, 8, 238212052110152.	0.7	3

Carlos Rodriguez-Galindo

#	Article	IF	CITATIONS
217	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	0.8	3
218	Multicenter study assessing tumor molecular profiles in advanced pediatric solid tumors Journal of Clinical Oncology, 2014, 32, 10011-10011.	0.8	3
219	IVADo treatment of type II and type III pleuropulmonary blastoma (PPB): A report from the International PPB Registry Journal of Clinical Oncology, 2014, 32, 10060-10060.	0.8	3
220	Rising drug cost impacts on costâ€effectiveness of 2 chemotherapy regimens for intermediateâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2021, 128, 317.	2.0	3
221	Cancer care for children in the Gaza Strip. Lancet Oncology, The, 2021, 22, 1667-1668.	5.1	3
222	Subsequent Malignant Neoplasm of Bone in Children and Adolescent—Possibility of Multimodal Treatment. Current Oncology, 2022, 29, 1001-1007.	0.9	3
223	Current treatment of Langerhans cell histiocytosis. Expert Opinion on Orphan Drugs, 2016, 4, 1057-1068.	0.5	2
224	Distal Tibial Reconstruction in the Management of Primary Bone Tumors in Children and Adolescents. Foot and Ankle International, 2021, 42, 107110072110126.	1.1	2
225	Survival after recurrence of Ewing Tumors. , 2002, 94, 561.		2
226	Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors. Blood, 2018, 132, 3684-3684.	0.6	2
227	Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group (COG) AHEP0731 study committee Journal of Clinical Oncology, 2016, 34, 10516-10516.	0.8	2
228	Carcinomas in the children and young adults: A report form Children's Oncology Group APEC14B1 study Journal of Clinical Oncology, 2019, 37, e21505-e21505.	0.8	2
229	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. Frontiers in Endocrinology, 2021, 12, 756523.	1.5	2
230	Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. JCO Global Oncology, 2022, 8, e2100266.	0.8	2
231	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
232	Reply to G. Mangili et al and C. Lhomm $ ilde{A}$ © et al. Journal of Clinical Oncology, 2014, 32, 2816-2817.	0.8	1
233	Intra-arterial chemotherapy for rhabdomyosarcoma. Pediatric Hematology and Oncology, 2021, 38, 391-396.	0.3	1
234	Pediatric Langerhans Cell Histiocytosis (LCH) Clinical Outcome in Hospital Civil De Guadalajara, México. Blood, 2018, 132, 4951-4951.	0.6	1

#	Article	IF	CITATIONS
235	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors Journal of Clinical Oncology, 2014, 32, 10052-10052.	0.8	1
236	Influence of early-phase clinical trial enrollment on patterns of end-of-life care for children with advanced cancer Journal of Clinical Oncology, 2016, 34, 151-151.	0.8	1
237	Rate of MYC-N gene amplification among children of Middle Eastern descent with neuroblastoma Journal of Clinical Oncology, 2018, 36, e22507-e22507.	0.8	1
238	Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group Journal of Clinical Oncology, 2019, 37, 10022-10022.	0.8	1
239	The Langerhans cell histiocytosis. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 335-336.	0.7	1
240	Elevated risk of second malignant neoplasms in pediatric germ cell tumor patients Journal of Clinical Oncology, 2013, 31, 10010-10010.	0.8	1
241	Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children's Oncology Group Journal of Clinical Oncology, 2016, 34, 10512-10512.	0.8	1
242	Molecular and MRD-Based Characterization of Acute Lymphoblastic Leukemia in Mexico: Experience from the <i>Mexico in Alliance with St. Jude</i> "Bridge Project". Blood, 2021, 138, 1209-1209.	0.6	1
243	Cancer care for displaced children from Venezuela. Lancet Oncology, The, 2021, 22, 1665-1666.	5.1	1
244	Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study. Pediatric Blood and Cancer, 2022, , e29556.	0.8	1
245	Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience. Medycyna Wieku Rozwojowego, 2019, 23, 39-44.	0.2	1
246	Adrenocortical Cancer in Children. , 2009, , 467-481.		0
247	THYROID CANCER IN LEBANESE CHILDREN AND ADOLESCENTS: A 15-Year Experience at a Single Institution. Pediatric Hematology and Oncology, 2009, 26, 339-447.	0.3	0
248	Blue Toe Syndrome. JAMA Ophthalmology, 2014, 132, 654.	1.4	0
249	Treatment of Relapsed and Refractory Langerhans Cell Histiocytosis in Children. , 2018, , 119-137.		0
250	Pediatric cancer communication in Guatemala Journal of Clinical Oncology, 2021, 39, e18508-e18508.	0.8	0
251	Reply to JG. Wang et al. Journal of Clinical Oncology, 2021, 39, 3088-3089.	0.8	0
252	Trilateral retinoblastoma. , 2007, , 438-440.		0

#	Article	IF	CITATIONS
253	Non-ocular tumors. , 2007, , 434-437.		0
254	Rare Tumors of the Peripheral Nervous System. Pediatric Oncology, 2012, , 431-452.	0.5	0
255	Socioeconomic status and incidence of pediatric embryonal tumors in the United States Journal of Clinical Oncology, 2013, 31, 10036-10036.	0.8	0
256	Impact of socioeconomic status on extent of disease at diagnosis and cancer and ocular outcomes in retinoblastoma: A population-based analysis Journal of Clinical Oncology, 2013, 31, 10011-10011.	0.8	0
257	Birth and maternal characteristics, and childhood cancer in the United States: An ecological study Journal of Clinical Oncology, 2013, 31, 10061-10061.	0.8	Ο
258	Correlation of insurance status, ethnicity, and race with pathologic risk in retinoblastoma: A Children's Oncology Group (COG) study Journal of Clinical Oncology, 2013, 31, e17573-e17573.	0.8	0
259	Open-label, multicenter, single-arm, phase I, dose-dscalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring <i>BRAF^{V600}</i> mutations (NCT01519323) Journal of Clinical Oncology, 2013, 31. TPS9104-TPS9104.	0.8	Ο
260	Evaluation of the necessity of bilateral bone marrow aspirates and biopsies for the diagnosis of metastatic disease in pediatric patients with solid tumors Journal of Clinical Oncology, 2013, 31, 10054-10054.	0.8	0
261	Pediatric Solid Tumors. , 2014, , 1804-1848.e12.		0
262	Risk of second thyroid cancer (STC) among survivors of childhood cancer Journal of Clinical Oncology, 2014, 32, 10084-10084.	0.8	0
263	Postrecurrence survival for pediatric extracranial malignant germ cell tumors: A report from the Malignant Germ Cell Tumors International Collaborative (MaGIC) Group Journal of Clinical Oncology, 2014, 32, 10074-10074.	0.8	0
264	Analysis of somatic copy number alterations in pediatric solid tumors using array comparative genomic hybridization Journal of Clinical Oncology, 2014, 32, 1538-1538.	0.8	0
265	Ethnic disparities in pediatric Ewing sarcoma and osteosarcoma Journal of Clinical Oncology, 2014, 32, 1614-1614.	0.8	0
266	A phase II study of sirolimus and erlotinib in recurrent/refractory germ cell tumors Journal of Clinical Oncology, 2014, 32, TPS2638-TPS2638.	0.8	0
267	Increased risk of second malignant neoplasms (SMN) in young children with embryonal rhabdomyosarcoma (ERMS): Evidence for a cancer predisposition syndrome?. Journal of Clinical Oncology, 2014, 32, 10042-10042.	0.8	0
268	Death less than one month from diagnosis in children with cancer: A population-based analysis Journal of Clinical Oncology, 2014, 32, 1531-1531.	0.8	0
269	RNA profiling of desmoplastic small round cell tumors (DSRCTs) using next-generation sequencing Journal of Clinical Oncology, 2016, 34, 10552-10552.	0.8	0
270	Contribution of the TP53 R337H mutation to the cancer burden in families with a proband with adrenocortical tumor Journal of Clinical Oncology, 2016, 34, 1538-1538.	0.8	0

#	Article	IF	CITATIONS
271	The cost and cost-effectiveness of a pediatric cancer unit (PCU) in the context of universal health coverage (UHC): A report from the Childhood Cancer 2030 Network Journal of Clinical Oncology, 2018, 36, e18891-e18891.	0.8	0
272	Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium Journal of Clinical Oncology, 2019, 37, 10036-10036.	0.8	0
273	Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study. Asian Pacific Journal of Cancer Prevention, 2022, 23, 631-640.	0.5	0
274	Rhabdomyosarcoma in low―and middleâ€income countries: A report from the Asociacion de Hematoâ€oncologÃa Pediatrica de Centro América (AHOPCA). Pediatric Blood and Cancer, 2022, , e29669.	0.8	0